Vinblastine-Sulfate Aqueous Injection
Each 10 ml vial contains Vinblastine Sulfate USP 10 mg, Sodium Chloride IP 90 mg and Benzyl Alcohol IP 0.9% v/v in sterile water for injection IP q.s.
Without a Prescription
Vinblastine-Sulfate is prescribed for the treatment of:
- Advanced testicular carcinoma;
- Vinblastine-Sulfate is an antineoplastic drug prescribed for use, either alone or in combination with other oncolytic drugs in the treatment of the following:;
- Frequently responsive malignancies;
- Histiocytic lymphoma;
- Hodgkin's disease;
- Kaposi's sarcoma and letterer-siwe disease;
- Mycosis fungoides;
- Non-hodgkin's lymphoma;
Less frequently responsive malignancies Choriocarcinoma resistant to other chemotherapeutic agents and carcinoma of the breast unresponsive to appropriate endocrine surgery and hormonal therapy.
This preparation is for intravenous use only.
Intrathecal use of the drug could be fatal.
Vinblastine-Sulfate may be injected either directly into a vein or into the tubing of a running intravenous infusion.
Injection of Vinblastine-Sulfate may be accomplished within one minute.
The dose should not be diluted in large volumes of diluent or given intravenously for prolonged periods (ranging from 30 to 60 minutes or more) since this frequently results in irritation of the vein and increases the chance of extravasation.
Vinblastine-Sulfate should be given no more frequently than once every seven days.
It is wise to initiate therapy for adults by administering a single intravenous dose of 3.7 /m 2 of body surface area (bsa) the initial dose for children should be 2.5 mg/m 2.
Thereafter white blood cell counts should be made to determine the patients' sensitivity to Vinblastine-Sulfate.
A simplified and conservative incremental approach to dosage at weekly intervals may be outlined as follows:
The above-mentioned increases may be used until a maximum dose (not exceeding 18.5 /m 2 bsa for adults and 12.5 mg/m 2 bsa for children) is reached.
The dose should not be increased beyond that dose which reduces the white cell count to approximately 3,000 cells/mm 3.
When the dose of Vinblastine-Sulfate which will produce the above degree of leukopenia has been established, a dose of one increment smaller than this should be administered at weekly intervals for maintenance.
It should be emphasised that even though 7 days have elapsed, the next dose of Vinblastine-Sulfate should not be given until the white blood cell count has returned to at least 4,000/mm 3.
If leukopenia with less than 2,000 white blood cells/mm 3 occurs, the patient should be watched carefully for evidence of infection until white blood cell count has returned to a safe level.
Vinblastine-Sulfate is contraindicated in patients who have significant granulocytopenia unless this is a result of the disease being treated.
It should not be used in the presence of bacterial infections.
The infections must be brought under control prior to initiating therapy.
- Vial of 10 ml;